Construction of immune-related risk signature for uveal melanoma
Source abstract
Abstract
Uveal melanoma (UM) is the most frequent primary ocular tumour among adults. Here, we aimed to establish the immune cell-based signature to predict the overall survival (OS) of UM patients. The mRNA profile and matched clinical records of 80 UM patients were downloaded from The Cancer Genome Atlas (TCGA) database. CIBERSORT was used to verify the immune cell types of individuals. The univariate analysis found the CD8+ T cell, monocyte, CD4+ memory T cell (resting) and mast cell (resting) were significantly associated with the OS of UM patients. Subsequently, the LASSO Cox regression test was applied to establish the signature, by which the patients were separated into high- and low-risk subgroups. The Kaplan-Meier analyses found for these patients in the high-risk group had a poor survival rate than those in the low-risk group. The predictive value and stability were confirmed by the receiver operative characteristics curves. Pathway analyses found that the differentially expressed genes between the high- and low-risk subgroups were mainly centralised on immune response-related pathways. Further, the comparison of our signature with clinicopathological records confirmed its superiority and independence. In summary, we established an immune cell-based prognosis-predicting signature for UM patients, which will benefit the individual's treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ocular Oncology and Treatments · Immunotherapy and Immune Responses · Veterinary Oncology Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University
School of Public Health, Sun Yat-sen University
References (28)
Show source-provided references
1. 10.1159/00048064010.1159/000480640 ↗
2. 10.1016/j.ophtha.2011.01.04010.1016/j.ophtha.2011.01.040 ↗
3. 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G ↗
4. 10.1002/cncr.2086610.1002/cncr.20866 ↗
5. 10.1038/eye.2012.12610.1038/eye.2012.126 ↗
6. 10.1016/j.ophtha.2012.01.04810.1016/j.ophtha.2012.01.048 ↗
7. 10.1136/bjophthalmol-2015-30681010.1136/bjophthalmol-2015-306810 ↗
8. 10.3389/fimmu.2012.0014810.3389/fimmu.2012.00148 ↗
9. 10.4049/jimmunol.156.8.266710.4049/jimmunol.156.8.2667 ↗
10. Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997;38(6):1277–1282.
11. 10.1167/iovs.07-160610.1167/iovs.07-1606 ↗
12. 10.1002/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X10.1002/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X ↗
13. Whelchel JC, Farah SE, McLean IW, et al. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993;34(8):2603–2606.
14. Makitie T, Summanen P, Tarkkanen A, et al. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(7):1414–1421.
15. 10.1167/iovs.10-597910.1167/iovs.10-5979 ↗
16. 10.1038/labinvest.2017.6410.1038/labinvest.2017.64 ↗
17. 10.1038/nmeth.333710.1038/nmeth.3337 ↗
18. 10.1167/iovs.07-078610.1167/iovs.07-0786 ↗
19. 10.1200/JCO.2005.02.653410.1200/JCO.2005.02.6534 ↗
20. 10.1007/s00280-019-03860-z10.1007/s00280-019-03860-z ↗
21. 10.2147/OPTH.S11362310.2147/OPTH.S113623 ↗
22. 10.2147/OPTH.S8959110.2147/OPTH.S89591 ↗
23. 10.1056/NEJMicm181059610.1056/NEJMicm1810596 ↗
24. 10.1634/theoncologist.2015-052210.1634/theoncologist.2015-0522 ↗
25. 10.1038/nature2134910.1038/nature21349 ↗
26. 10.1186/s40425-019-0585-110.1186/s40425-019-0585-1 ↗
27. 10.1167/iovs.07-103510.1167/iovs.07-1035 ↗
28. 10.1007/s00262-007-0303-610.1007/s00262-007-0303-6 ↗